Voya Investment Management LLC Decreases Stake in Krystal Biotech, by 2.0% in Q4
June 29, 2023
🌥️Trending News
Krystal Biotech ($NASDAQ:KRYS), Inc. is a gene therapy company, focused on developing and commercializing transformative treatments to cure patients suffering from skin diseases. The company has developed a proprietary platform to deliver gene therapy product candidates with the goal of improving the lives of patients with severe skin conditions. Voya Investment Management LLC disclosed in its most recent filing with the Securities & Exchange Commission that its stake in Krystal Biotech, Inc. had decreased by 2.0% during the 4th quarter. This decrease in stake was part of the company’s overall portfolio management strategy, and it is uncertain why it chose to reduce its holdings in this particular stock.
However, this did not appear to have had an effect on Krystal Biotech’s share price, which has remained relatively stable since the filing. Despite the decrease in stake, Voya Investment Management LLC remains a major shareholder of Krystal Biotech, Inc., and the company’s future performance will continue to be watched closely. With a promising platform for gene therapy products, Krystal Biotech may be able to realize its mission of improving the lives of patients with severe skin conditions in the near future.
Analysis
At GoodWhale, we recently conducted an analysis of KRYSTAL BIOTECH‘s well-being. Based on our Risk Rating, KRYSTAL BIOTECH is a medium risk investment in terms of financial and business aspects. From our analysis, we detected three risk warnings in their income sheet, balance sheet, and cashflow statement. If you would like to view our full report and see the exact warnings we found, please register on goodwhale.com. We hope our analysis helps you make the best decision for your investments. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Krystal Biotech. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -135.31 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Krystal Biotech. More…
| Operations | Investing | Financing |
| -111.23 | -54.61 | 37.36 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Krystal Biotech. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 531.85 | 42.28 | 18.98 |
Key Ratios Snapshot
Some of the financial key ratios for Krystal Biotech are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | – |
| FCF Margin | ROE | ROA |
| – | -18.7% | -17.8% |
Peers
The company is among several biopharmaceutical companies in the industry, including GT Biopharma Inc, Jounce Therapeutics Inc, and CytomX Therapeutics Inc, that are focused on developing innovative treatments for serious diseases.
– GT Biopharma Inc ($NASDAQ:GTBP)
GBT Biopharma Inc is a biopharmaceutical company that develops and commercializes treatments for cancer and other diseases. The company has a market cap of 35.49M as of 2022, which is relatively low compared to the market cap of many larger biopharmaceutical companies. Additionally, the company has a negative Return on Equity (ROE) of -132.59%, which indicates that the company is not able to generate profits from its investments and is likely not a good investment option.
– Jounce Therapeutics Inc ($NASDAQ:JNCE)
Jounce Therapeutics Inc is a biopharmaceutical company focused on developing therapies to improve the lives of people with cancer. The company currently has a market cap of 40.84M, making it relatively small when compared to other biotechnology companies in the sector. In terms of Return on Equity, Jounce Therapeutics Inc has a negative ROE of -57.85%. This reflects the company’s inability to generate profits and its need for additional capital to finance its operations. Despite these challenges, the company remains committed to its mission of developing innovative treatments for cancer patients.
– CytomX Therapeutics Inc ($NASDAQ:CTMX)
CytomX Therapeutics Inc is a biopharmaceutical company that develops innovative therapeutics for oncology and other diseases. The company’s market cap as of 2022 is 102.43M, indicating that the company has a moderate amount of liquidity and is in a good position to invest in its operations. However, its Return on Equity (ROE) of -160.27% suggests that the company has not been able to generate profits from its investments and is struggling to achieve positive earnings. This could be due to the high cost of research and development, or a lack of focus on core business activities.
Summary
Krystal Biotech, Inc. is a clinical-stage gene therapy company focused on developing and commercializing transformative treatments for patients with dermatological diseases. The same day, Krystal Biotech’s stock price decreased. This may indicate a lack of confidence in the company’s performance, or investors deciding to take profits from the stock.
Analysts will be closely watching the company’s performance in the coming months to determine if this was a sign of an underlying trend or an aberration. Investors should also pay attention to any changes in Krystal Biotech’s business strategy or financial performance as they could influence its stock price.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
